AIM ImmunoTech
11 hedge funds and large institutions have $578K invested in AIM ImmunoTech in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 1 closing their positions.
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
60% more capital invested
Capital invested by funds: $362K → $578K (+$216K)
57% more funds holding
Funds holding: 7 → 11 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.25M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$957K |
| 3 |
Morgan Stanley
New York
|
+$349K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$301K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.18K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Hudson Bay Capital Management
Stamford,
Connecticut
| $301K | +$957K | +3,953 | New |
|
|
SM
2
Sabby Management
Miami Beach,
Florida
| $141K | +$301K | +1,245 | +204% |
|
|
3
Morgan Stanley
New York
| $110K | +$349K | +1,440 | New |
|
|
ARTA
4
A.R.T. Advisors
New York
| $9K | +$5.81K | +24 | +24% |
|
5
BlackRock
New York
| $8K | – | – | – |
|
|
6
Bank of America
Charlotte,
North Carolina
| $8K | +$24.7K | +102 | New |
|
|
AFM
7
Anson Funds Management
Dallas,
Texas
| $393 | +$1.25M | +5,156 | New |
|
|
APA
8
American Portfolios Advisors
Holbrook,
New York
| $174 | – | – | – |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$2.18K | -9 | Closed |
|
10
Victory Capital Management
San Antonio,
Texas
| – | +$968 | +4 | New |
|
AIM Hedge Fund Activity: Q3 2019 in Review
11 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2019, worth a combined $578K — up 60% from $362K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AIM positions and 1 closed out — a net gain of 4 holders — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.25M. The largest seller was UBS Group, exiting entirely with an estimated $2.18K sold.
- 11 institutional investors held AIM ImmunoTech (AIM) as of Q3 2019, up from 7 in Q2 2019.
- Funds reported $578K of AIM ImmunoTech stock for Q3 2019, up 60% quarter-over-quarter.
- 5 funds opened new AIM ImmunoTech positions in Q3 2019 and 1 closed out, a net change of +4 holders.
- The largest AIM ImmunoTech buyer in Q3 2019 was Anson Funds Management, an estimated $1.25M added.
- The largest AIM ImmunoTech seller in Q3 2019 was UBS Group, an estimated $2.18K sold.
Based on aggregated 13F filings for Q3 2019.